Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus CAG for Refractory/Relapsed AML
NCT05918198Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML), sponsored by Peking University People's Hospital. Primary endpoint: Complete Remission/Complete Remission with Incomplete Hematologic Recovery Rate. Started Feb 2023; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05918198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918198.